Plné znění - 47/2014 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod - Mezinárodní standard) Mezinárodní úmluvy proti dopingu ve sportu

47/2014 Sb. m. s.

Sdělení

INFORMACE

47

XXXXXXX

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,

xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 58/2007 Xx. m. x. x x. 46/2008 Xx. x. x. x xxxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 98/2013 Xx. x. x. x Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx

Xxxxxxxxxxxx xxxxxxxxxxxx věcí xxxxxxx, že dne 11. xxxxxxxxx 2013 xxxx generální ředitelkou XXXXXX oznámeno xxxxxxxxx xxxxxx znění Xxxxxxx X - Xxxxxxx xxxxxxxxxx xxxxx a xxxxx - Mezinárodní xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx ve xxxxxx.¹⁾

X xxxxx xxxxxx Xxxxxxx X vyslovil xxxxxxx Parlament České xxxxxxxxx x xxxxxxxxx xxxxxxxxx podepsal xxxxxxx x přijetí změny Xxxxxxx X Českou xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx X xxxxxxxxx x xxxxxxxx x souladu x xxxxxxx 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2014 x tímto xxxx xxxxxxxxx v xxxxxxxx i xxx Xxxxxx xxxxxxxxx. Xxxx xxxxxx xxxxxx znění Xxxxxxx X x xxxxxxxx xxxxxxxx xxxxxx xxxxx Přílohy I Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx sportu xxxxxx xx 1. xxxxx 2013 x xxxxxxxxx xxx č. 98/2013 Sb. m. s.

Xxxxxxxx xxxxx Xxxxxxx I x její xxxxxxx xx českého xxxxxx xx xxxxxxxxx současně.

¹⁾ Xxxxxxxxxxx xxxxxx proti xxxxxxx ve xxxxxx xxxxxxx dne 19. xxxxx 2005 x Xxxxxx xxxx xxxxxxxxx xxx č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

XXXXXXXXXXX XXXXXX PROTI XXXXXXX VE SPORTU
Příloha X - Xxxxxx xxxxxxxxxx xxxxx a xxxxx - Xxxxxxxxxxx xxxxxxxx
Xxxxx, 1. xxxxx 2014

XXXXXX XXXXXXXXXX XXXXX X XXXXX XXXXXXX XXX XXX 2014

XXXXXXX XXXXXXXXXXXXX KODEX

Platný od 1. ledna 2014

Xxxxx xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx xxxxx xxxxx xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" kromě látek xx xxxxxx S1, X2, S4.4, X4.5 x S6(a) a Xxxxxxxxxx metod M1, X2 x X3.

XXXXX X METODY ZAKÁZANÉ XXXXX (XXX SOUTĚŽI I XXXX SOUTĚŽ)

ZAKÁZANÉ XXXXX

X0. XXXXXXXXXXX XXXXX

Xxxxxxxxx xxxxxxxxxxxxx xxxxx, xxxxx xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Xxxxxxx a xxxx aktuálně xxxxxxxxx xxx humánní xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxx (xxxx. xxxxxx x xxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxx xxxx xx xxxxxxxx registraci, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxxxx), xx xxxxxxxx xxxxx.

X1. ANABOLICKÉ XXXXX

Xxxxxxxxxx látky xxxx xxxxxxxx.

1. XXXXXXXXXX ANABOLICKÉ XXXXXXXX (AAS):

(a) Xxxxxxxx* XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3x,17β-xxxx); 1-xxxxxxxxxxxxx (5α-androst-1-en-3,17-dion); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); danazol ([1,2]xxxxxx[4',5':2,3]xxxxxx-4-xx-20-xx-17α-xx); dehydrochlormethyltestosteron (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-methyl-5α-androst-2-en-17β-ol); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-xxxxxx-4-xx-17α-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17α-methyl[1,2,5]oxadiazolo[3',4':2,3]-5α-androstan-17β-ol); xxxxxxxxx; 4-hydroxytestosteron (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; metandienon (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx; xxxxxxxxx; 19-norandrostendion (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; norklostebol; xxxxxxxx; xxxxxxxxxx; oxymesteron; xxxxxxxxxx; xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1'X-xxxxxxxx[3,4,:2,3]-5α-xxxxxxxxxx); xxxxxxxxx; xxxxxxxxxx; stenbolon; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx (17β-xxxxxxxxxx-4,9,11-xxxxx-3-xx) x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxx** XXX, xxxxx jsou xxxxxx xxxxxxxx:

Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), dihydrotestosteron, xxxxxxxxx (dehydroepiandrosteron, XXXX), 3β-xxxxxxxxxxxxx-5-xx-17-xx), xxxxxxxxxxx x xxxxxx xxxxxxxxxx x xxxxxxx, xxx ne x omezením xxxxx xx ně:

5α-androstan-3α,17α-diol	5-androstendion (androst-5-en-3,17-dion)
5α-androstan-3α,17β-diol	epi-dihydrotestosteron
5α-androstan-3β,17α-diol	epitestosteron
5α-androstan-3β,17β-diol	etiocholanolon
androst-4-en-3α,17α-diol	3α-hydroxy-5αandrostan-17-on
androst-4-en-3α,17β-diol	3β-hydroxy-5αandrostan-17-on
androst-5-en-3β,17α-diol	7α-hydroxy-DHEA
androst-5-en-3α,17α-diol	7β-hydroxy-DHEA
androst-5-en-3α,17β-dioI	7-keto-DHEA
androst-5-en-3β,17α-diol	19-norandrosteron
4-androstendiol (xxxxxxx-4-xx-3β,17β-xxxx)	19-xxxxxxxxxxxxxxxxx

Xxx xxxxx skupiny xxxx xxxxx:

* "xxxxxxxx" xx xxxxxxxx x xxxxx, xxxxxx xxxx xxxxxxxx xxxxxxxxx xxxxxxxxxxx.

** "xxxxxxxxx " xx xxxxxxxx x látce, xxxxxx xxxx xxxxxxxx xxxxxxxxx produkuje.

2. Ostatní xxxxxxxxxx xxxxx, zahrnující:

Klenbuterol, xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, xxxxxxxxxx, ale xx s xxxxxxxx xxxxx xx xx.

X2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX A XXXXXXXX XXXXX

Xxxxxxxxxxx látky a xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx biologickými xxxxxx jsou xxxxxxxx:

1. Xxxxx xxxxxxxxxxx erytropoesu (xxxx. xxxxxxxxxxxx (EPO), xxxxxxxxxxx (xXXX), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx beta (XXXX), xxxxxxxxxxx /Hematide/);

2. Xxxxxxxxxxxxxxxxxx (XX) a Xxxxxxxxxxxx xxxxxx (LH) x xxxxxx uvolňující xxxxxxx u mužů;

3. Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx xxxxxxx;

4. Xxxxxxx xxxxxx (XX) a xxxx xxxxxxxxxx xxxxxxx x insulinu xxxxxxx xxxxxxx xxxxxx-1 (IGF-1).

Kromě xxxx xxxx xxxxxxxx xxxxxxxxxxx xxxxxxx xxxxxxx:

Xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXXx), xxxxxxxxxxxx xxxxxxx faktor (XXX), xxxxxxxxxx xxxxxxx xxxxxxx (XXX), růstový xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX) x vaskulárně-endoteliární xxxxxxx xxxxxx (XXXX), xxxxxx xxxx xxxxxxxxx xxxx xxxxxxx faktory xxxxxxxxxxx xxxxxxx nebo xxxxxxxxx xxxxxxxx xxxxx, šlach x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx kapacitu nebo xxxxxxxxxxx xxxx svalových xxxxxx;

x další látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx.

X3. XXXX2- XXXXXXXX

Xxxxxxx beta-2 xxxxxxxx, xxxxxx xxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. x- x x-), xxxx xxxxxxxx xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxxxxxxx 1600 mikrogramů xx 24 hodin), inhlalačního xxxxxxxxxxx (xxxxxxxxx podaná xxxxx 54 xxxxxxxxxx xx 24 xxxxx) x xxxxxxxxxxx, xxxxx xxxx xxxxxx x xxxxxxxx x xxxxxxx x xxxxxxxxxxx léčebným xxxxxxx xxxxxxx.

Xxxxxxxxxx salbutamolu x xxxx x xxxxxxxxxxx xxxxx xxx 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx x xxxx x koncentraci xxxxx než 40 xx/xx xxxxxx xxxxxxxxxx xx zamýšlené xxxxxxxxxxxx xxxxxxx, ale xxxx xxxxxxxxxx xx pozitivní xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx studií, xx xxxxxxxxxx výsledek xxx xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx xxxxx xxx xxxx uvedené xxxxxxx.

X4. XXXXXXXXX A XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Inhibitory aromatáz, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx), 4-xxxxxxxxx-3,6,17-xxxxx (6-oxo), xxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx xx x omezením pouze xx xx.

2. Selektivní xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxxxx:

Xxxxxxxxx, tamoxifen, xxxxxxxxx, ale ne x xxxxxxxx pouze xx xx.

3. Xxxxxxx xxxxxxxxxxxxxx xxxxx zahrnující:

Cyklofenil, xxxxxxxxxxx, xxxxxxxx, xxx xx s xxxxxxxx xxxxx xx ně.

4. Xxxxx modifikující funkce xxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.

5. Metabolické xxxxxxxxxx:

x) Insuliny;

b) Receptor xxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx /Peroxisome Proliferator Xxxxxxxxx Xxxxxxxx δ (XXXXδ) agonists/ (xxxx. XX 1516) a Xxxxxxxx xxxxxxxxxxxxxxx xxx xxxxxxxxxx XXX x xxxxxxxxxxx x XXXX xxxxx /XXXXδ-XXX-xxxxxxxxx xxxxxxx xxxxxx (XXXX) xxxx xxxxxxxx/ (xxxx. XXXXX)

X5. XXXXXXXXX X XXXXXXX XXXXXXXXX XXXXX

Xxxxxxxxx látky xxxx xxxxxxxx. Zahrnují:

Diuretika, xxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, xxxxxxxxxx podání xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), probenecid x další xxxxx x xxxxxxxxx biologickými xxxxxx. Xxxxxxx xxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxx xxxx xxxxxxxx.

Xxxxxxxxx xxxxxxxx:

Xxxxxxxxxxxx, amilorid, bumetanid, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, kyselina etakrynová, xxxxxxxxx, spironolakton, xxxxxxxx (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), triamteren, xxxxxxx (xxxx. xxxxxxxxx) a xxxxx xxxxx x xxxxxxxx chemickou strukturou xxxx xxxxxxxxx biologickými xxxxxx (kromě xxxxxxxxxxxx, xxxxxxxxx x lokálního xxxxxx xxxxxxxxxxx a xxxxxxxxxxxx, které nejsou xxxxxxxx).

Xxx xxxxxxx (Při Xxxxxxx, xxxxxxxx Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxx limitem (tj. xxxxxxxxxx, salbutamol, xxxxx, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) ve xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx látkou xx xxxxxxxxxx xxxxxxx xxxxxxxxxx Terapeutické výjimky xx xxxx xxxxx xxxxx x xx, xxxxx xxx byla xxxxxxx xx diuretikum xxxx xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

X1. MANIPULACE X KRVÍ X XXXXXXXX KOMPONENTAMI

Zakázané xx xxxxxxxxxxx:

1. Xxxxxx xxxx xxxxxxxxxxxxx jakéhokoliv xxxxxxxx xxxxxxxxx, alogenní (xxxxxxxxx) xxxx xxxxxxxxxxx krve xxxx xxxxxxxxx xxxxxxx x jim xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx xx oběhového xxxxxxx.

2. Xxxxx xxxxxxxxx spotřeby, xxxxxxx xxxx xxxxxxx xxxxxxx, xxxxxxxxxx modifikované xxxxxxxxxxxxx produkty (např. xxxxxx xxxxxxxx založené xx xxxxxxxxxxx, mikroenkapsulované xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), xxx xx s xxxxxxxx xxxxx xx xx. Xxxxxxxxxxxx kyslíkem xxxxxxxx xxxx.

3. Jakákoliv xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx nebo x xxxxxxxx xxxxxxxxxxxx fyzikálními xxxx xxxxxxxxxx způsoby.

M2. XXXXXXXX A XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

1. Xxxxxxxxx, nebo pokus x xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx x xxxxxxxx Vzorků xxxxxxxxxx xxx Dopingové xxxxxxxx. Xx zahrnuje xxxxxx x/xxxx úpravu (xxxx. xxxxxxxxxx) xxxx, xxx ne s xxxxxxxx xxxxx xx xx.

2. Xxxxxxxxxx infuze x/xxxx xxxxxxx xxxx xxx 50 xx xx 6 xxxxx xxxxx xxxxxx legitimně xxxxxxxxx v xxxxxxx xxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx vyšetřovacích metod.

M3. XXXXXX XXXXXX

X důvodu xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:

1. Xxxxxxxx xxxxxxxx xxxxxxxxxx kyselin xxxx xxxxxx xxxxxxx;

2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx buněk.

LÁTKY X METODY XXXXXXXX XXX XXXXXXX

Xxxxx kategorií X0 xx S5 x X1 xx X3 xxxxxxxxx xxxx xxxx Při Xxxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxx:

XXXXXXXX LÁTKY

S6. STIMULANCIA

Všechna xxxxxxxxxxx včetně xxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. d- x x-) xxxx xxxxxxxx, x xxxxxxxx xxxxxxxx imidazoiu v xxxxxxx xxxxxx místního xxxxxxx a stimulancií xxxxxxxxxx xx Monitorovacího xxxxxxxx pro rok 2014*.

Xxxxxxxxxxx zahrnují:

(a) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx, xxxxxxxxxx, amfetamin, xxxxxxxxxxx, xxxxxxxxxx, benfluorex, xxxxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx /4-fenylpiracetam (xxxxxxxx)/, xxxxxxxxxx, klobenzorex, xxxxxx, xxxxxxxxxxx, krotetamid, mefenorex, xxxxxxxxxxx, xxxxxxxxxxxx (x-), xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, prenylamin, xxxxxxxxx.

Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxx x tomto xxxxxxxx, je Xxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxxx stimulancia (xxxxxxxx):

Xxxxxxxxx (xxxxxxxxx)****, xxxxxxxxxxx, xxxxxxxxxxxxxxxxx, efedrin***, xxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, fenprometamin, xxxxxxxxxx, xxxxxxxxxxxxxxxx (parahydroamfetamin), xxxxxxxxxxxx, xxxxx**, xxxxxxx x xxxx xxxxxxx (xxxx. xxxxxxxx, xxxxxxxxx, xxxx-xxxxxxxxxxxxxxxxxxxxx), xxxxxxxxxxxxxxx, meklofenoxát, xxxxxxxxxxxx***, metylendioxymetamfetamin, xxxxxxxxxxxx, xxxxxxxxxxxxxx (dimetylpentylamin), níketamid, xxxxxxxxxxx, oktopamin, xxxxxxxxx (xxxxxxxxxxxxx), xxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****, selegilin, xxxxxxxxxx, strychnin, xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx), xxxxxxxxxxxx, tuaminoheptan x další xxxxx x podobnou chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

* Následující xxxxx xxxxxxxx do Xxxxxxxxxxxxxx programu 2014 (xxxxxxxxx, xxxxxxxxxx, fenylpropanolamin, xxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxx) nejsou považovány xx Zakázané xxxxx.

** Xxxxx xx xxxxxxxx xxxxx při xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx xxxx.

*** Efedrin x methylefedrin jsou xxxxxxxx xxx koncentraci xxxxx než 10 xxxxxxxxxx v 1 xx xxxx.

**** Lokální xxxxxx xxxxxxxxxx (xxxxxxxxxx) (xxxx. xxxxx, oční xxxxxxxx) nebo xxxx xxxxxx xxxxxxxx x xxxxxxxxx anestetiky xxxx xxxxxxxx.

***** Xxxxxxxxxxxxx xx xxxxxxx, xxxxx xxxx xxxxxxxxxxx x xxxx xx vyšší xxx 150 xxxxxxxxxx na xxxxxxxx.

X7. NARKOTIKA

Zakázané je xxxxxxxxxxx:

Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx x jeho xxxxxxxx, hydromorfon, xxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx.

X8. XXXXXXXXXXX

Xxxxxxxx (xxxx. hašiš, konopí x xxxxxxxxx) xxxx xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) x xxxxxxxxxxxxxx (xxxx. "Xxxxx", JWH018, XXX073 x HU-210) xxxx xxxxxxxx.

X9. XXXXXXXXXXXXXXXXXXXX

Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, rektálně, xxxxxxxxxx nebo xxxxxxxxxxxxx xxxxxxxx jsou zakázané.

LÁTKY XXXXXXXX X URČITÝCH XXXXXXXX

X1. XXXXXXX

Xxxxxxx (xxxxxx) xx xxxxxxxx xxxxx Xxx Soutěži x xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx xxxx xxxxxxxx xxxxxxxx zkouškou x/xxxx xxxxxxxx krve. Prahová xxxxxxx pro xxxxxxxx xxxxxxxxxxx xxxxxxxx xx xxxxxxxxxxxx koncentrací xxxxxxxx x xxxx 0.10 x/x.

• Automobilový xxxxx (XXX)

• Xxxxxx (XXX)

• Xxxxxxx xxxxxx x xxxxxxxxxxxx (FAI)

• Lukostřelba (XX)

• Xxxxxxxxxxx xxxxx (XXX)

• Xxxxx xxxxxxxxxx (XXX)

X2. XXXX-XXXXXXXXX

Xxxxx xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx Xxx Xxxxxxx v xxxxxxxxxxxxx xxxxxxxx.

• Xxxxxxxxxxxx xxxxx (XXX)

• Billiard (xxxxxxx discipliny) (XXXX)

• Xxxx (IGF)

• Lukostřelba (XX) (xxxxxxxx xxxx Xxxx soutěž)

• Xxxxxxxx (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx lyžování-skoky x X-xxxxx, x snowboard X-xxxxx a "xxx xxx"

• Střelba (XXXX, XXX) (xxxxxxxx xxxx Xxxx soutěž)

• Xxxxx (XXX)

Xxxx-xxxxxxxxx zahrnují následující xxxxx:

Xxxxxxxxxx, xxxxxxxxxx, atenolol, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, esmolol, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxxx, ale xx x xxxxxxxx xxxxx na xx.

Informace

Právní xxxxxxx x. 47/2014 Sb. m. x. xxxxx xxxxxxxxx xxxx 20.9.2014.

Xxxxxx xxxxxxx x. 47/2014 Sb. x. x. xxx xxxxxx právním xxxxxxxxx č. 19/2017 Sb. m. s. x xxxxxxxxx xx 6.4.2017.

Xxxxx jednotlivých xxxxxxxx xxxxx xxxxxx xxxxxxxx předpisů x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx se xxxx xxxxxx xxxxxxxxx xxxxx xxxxx uvedeného xxxxxxxx xxxxxxxx.